Minimal change disease (MCD) is caused by damage to the kidney’s filtering cells, but in most cases, the exact trigger remains unknown. What researchers do know is that the immune system plays a central role, attacking or disrupting the delicate structures in the kidney that normally keep protein in the blood. It is the most common cause of nephrotic syndrome in children and accounts for 10 to 15% of primary nephrotic syndrome cases in adults.
How the Kidney’s Filters Get Damaged
Your kidneys contain millions of tiny filtering units called glomeruli. Each one is lined with specialized cells called podocytes, which have finger-like extensions (foot processes) that interlock to form a barrier. This barrier lets waste pass into urine while keeping essential proteins, especially albumin, in your blood.
In MCD, those foot processes flatten and spread out, a change visible only under an electron microscope. When the foot processes collapse, gaps open in the filter, and protein spills into the urine. Under a standard microscope, kidney tissue looks completely normal, which is where the disease gets its name. Immunofluorescence testing, which looks for immune deposits, also comes back essentially clean. The only consistent finding is that flattening of foot processes on electron microscopy.
Recent research has uncovered another layer to the damage. The inner lining of the kidney’s blood vessels is coated with a sugar-rich protective layer called the glycocalyx. In MCD, enzymes appear to strip away a key component of this coating (heparan sulfate), making the vessel walls more permeable to albumin. Podocytes normally support the health of these blood vessel cells by producing a growth signal called VEGF, and studies have found that VEGF production is decreased in MCD. This creates a vicious cycle: injured podocytes can no longer protect the blood vessel lining, and the damaged lining allows even more protein to leak through.
The Immune System’s Role
MCD has long been considered a disease driven by immune dysfunction, and for good reason. It responds dramatically to drugs that suppress the immune system, and flares often follow infections or allergic reactions. The traditional theory pointed to T cells as the main culprit, with overactive immune cells releasing substances that directly injure podocytes.
The picture has grown more complex. Researchers now recognize that multiple branches of the immune system are involved at different stages of the disease. One important finding is that patients with active MCD have reduced numbers of regulatory T cells, a specialized subset of immune cells that normally dial down inflammation. When these regulatory cells are outnumbered by inflammatory immune cells, the balance tips toward kidney damage. Animal studies have shown that directly infusing regulatory T cells or stimulating their growth can protect against the kind of kidney injury seen in MCD.
B cells, the immune cells responsible for producing antibodies, also appear to play a role. A striking recent discovery identified autoantibodies that target nephrin, a critical protein in the podocyte’s filtration barrier, in a subgroup of MCD patients. This finding helps explain why some patients respond well to treatments that deplete B cells, and it suggests that MCD may have an autoimmune component in at least some cases.
Primary (Idiopathic) MCD
The majority of MCD cases, especially in children, are idiopathic, meaning no identifiable external cause can be found. In these cases, the immune dysfunction appears to arise on its own. Several circulating factors have been proposed as the substances that damage podocytes, including activated forms of hemopexin, a blood protein that in laboratory experiments causes both podocyte injury and breakdown of the protective glycocalyx lining blood vessels. Despite decades of research, no single “permeability factor” has been definitively confirmed as the universal trigger.
Genetic Susceptibility
MCD is not inherited in a straightforward way, but genetics can increase vulnerability. A significant association has been found between MCD and certain variants in the HLA-DQA1 gene, which is part of the immune system’s machinery for recognizing threats. This connection reinforces the idea that an abnormal immune response is at the core of the disease.
Whole-exome sequencing studies have also identified mutations in genes that directly affect podocyte structure. Mutations in the EMP2 gene, which helps regulate how podocytes handle cholesterol and albumin, have been linked to the disease. Mutations in the KANK gene have been found in families with steroid-sensitive nephrotic syndrome and in some cases that don’t respond to steroids. These genetic findings are rare but reveal specific ways that podocytes can be structurally vulnerable from birth.
Medications That Can Trigger MCD
In adults, secondary causes account for up to 15% of MCD cases, and medications are among the most well-documented triggers. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen are the most commonly implicated. Lithium, widely used for bipolar disorder, is another established cause. In drug-induced cases, the disease typically develops after weeks to months of use and often resolves once the medication is stopped, though immunosuppressive treatment is sometimes still needed.
Cancer-Related MCD
MCD can occasionally appear as a paraneoplastic syndrome, meaning it develops as a consequence of cancer rather than from direct tumor invasion of the kidneys. The strongest association is with Hodgkin lymphoma. The connection is well enough established that new-onset MCD in an older adult sometimes prompts screening for underlying malignancy. MCD has also been linked to solid tumors including thymoma, colorectal carcinoma, and renal cell carcinoma, though these associations are less common. In paraneoplastic cases, treating the underlying cancer often leads to remission of the kidney disease.
Allergic and Environmental Triggers
Allergic reactions and infections are recognized triggers for MCD flares, particularly in people who already have the disease. Case reports have documented relapses following bee stings, respiratory infections, and seasonal pollen exposure. One well-documented case involved a woman with seasonal allergic rhinitis whose MCD relapsed in a remarkably regular pattern each year during allergy season, with respiratory symptoms preceding each episode of nephrotic syndrome. The pattern suggested that her immune response to pollen was cross-reacting with kidney structures, similar to a delayed-type hypersensitivity reaction.
This overlap between allergy and MCD is not coincidental. Children with MCD have higher rates of atopic conditions like eczema, asthma, and food allergies compared to the general population. The shared thread appears to be an immune system that is primed to overreact, with the kidney’s filtering cells caught in the crossfire.
Why These Causes Matter for Treatment
Understanding the cause shapes how MCD is managed. Idiopathic cases in both children and adults typically respond well to corticosteroids, with most patients achieving remission. However, relapse is common, and some patients cycle through repeated episodes. For drug-induced MCD, removing the offending medication is the first step. For cancer-related cases, treating the malignancy takes priority. And for patients whose disease appears driven by allergic triggers, managing the underlying allergy may help prevent flares.
The emerging understanding of B cell involvement and anti-nephrin antibodies is reshaping how doctors think about resistant cases. Patients who don’t respond to traditional immunosuppression or who relapse frequently may benefit from therapies that target B cells specifically. The identification of specific genetic mutations also opens the door to more personalized approaches, particularly for the small number of patients whose disease has a clear hereditary basis.